1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Marketing & Advertising

NAD Dispute Over Native Deodorant Claims Raises Question: Is Wetness Protection Exclusive To Antiperspirants?

 
• By Lauren Nardella and Ryan Nelson

Colgate’s Tom’s of Maine continues efforts to police natural deodorant advertising, challenging wetness-protection claims from P&G’s Native brand in the National Advertising Division’s self-regulatory forum. Siding with Tom’s, the NAD focused on the adequacy of Native’s evidence, but the case also has FDA regulatory implications and could impact other P&G brands, namely Secret. Native is appealing the NAD’s decision.

Sweating Underarm

Procter & Gamble Co.’s Native deodorants brand failed to convince the National Advertising Division that its lab testing and consumer perception evidence adequately support claims about absorbing moisture and protecting against underarm wetness, following a challenge from Colgate-Palmolive Co.’s Tom’s of Maine.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

Alfasigma Seeking Slice Of EU’s Largest OTC Market With German Launch

 
• By Tom Gallen

Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.

Maxwellia Launches UK TV Campaign For Evana Showing Reality Of Menstruation

 
• By David Ridley

Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”

Haleon Launches ‘Prescription Strength’ Hayfever Remedy In The UK

 
• By David Ridley

Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”

Haleon’s US Eroxon Launch Falls Short Of Expectations

 
• By Tom Gallen

Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.

More from Business

Euro Q1 Consumer Health Earnings Preview: Haleon, Reckitt, Bayer

 
• By Tom Gallen

Major Europe-based consumer health players Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q1 2025 results over the coming weeks.

Futura Records First Profits And Targets Eroxon Extension

 
• By Tom Gallen

The US launch of Eroxon ED treatment by Haleon helped Futura Medical record its first ever profit in 2024. The UK firm will now look to capitalize this by seeking US and EU approval for a more potent Eroxon line extension.

Australia’s Wellnex Life Poised To Enter UK’s CHC Market

 
• By Tom Gallen

Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.